CVR 32478980Public limited company (A/S)Engroshandel med medicinalvarer og sygeplejeartikler (464610)Secondary industries: Engroshandel med kemiske produkter (468500)HedenstedFounded 8 Oct 2009
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Caldic Denmark A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
8
CVR, Aug 2026
0 (0%) over 12 months
Revenue
76.5M
DKK, annual report 2025
-36.3% on 2024
Result
+4.7M
DKK, annual report 2025
Equity
24M
DKK, annual report 2025
Caldic BV100% of capital and votes, since 1 May 2016
Operating company
Dandex estimate: 8 employees registered in 2026Peter Kristian Faaborg-Andersensince 11 Sep 2026
100% of capital and votessince 1 May 2016
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR 16545996100% of capital and votes8 Oct 2009 to 30 Apr 2016
Decided by Dandex with fixed rules from CVR and the filed annual reports, and for the auditor's report a calibrated decision model reading the auditor's text, not registered by the company. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
4 Nov 2021 to 13 Nov 2026.
8 Oct 2009 to 13 Nov 2026.
Aug 2026, monthly: 8 employees, 7 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Q1 2010 | Q2 2010 | Q3 2010 | Q4 2010 | 2011 | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | No count | No count | No count | No count | 2 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 10 | 10 | 10 | 11 | 10 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 11 | 12 | 13 | 13 | 13 | 12 | 12 | 13 | 13 | 14 | 12 | 12 | 13 | 11 | 12 | 11 | 11 | 12 | 12 | 10 | 12 | 17 | 12 | 12 | 12 | 12 | 11 | 10 | 11 | 11 | 11 | 11 | 10 | 16 | 11 | 11 | 11 | 12 | 11 | 12 | 12 | 12 | 9 | 9 | 10 | 11 | 11 | 12 | 10 | 10 | 10 | 11 | 11 | 11 | 10 | 10 | 11 | 15 | 11 | 10 | 10 | 11 | 11 | 10 | 10 | 10 | 10 | 11 | 11 | 10 | 14 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| FTE | 2 | 2 | 2 | 2 | 1 | 4 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 10 | 9 | 10 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 10 | 11 | 11 | 11 | 12 | 10 | 11 | 12 | 12 | 13 | 11 | 11 | 11 | 10 | 11 | 9 | 10 | 11 | 10 | 9 | 10 | 15 | 11 | 11 | 9 | 10 | 10 | 9 | 11 | 11 | 10 | 11 | 9 | 12 | 11 | 11 | 9 | 12 | 10 | 11 | 12 | 11 | 8 | 9 | 9 | 10 | 10 | 11 | 10 | 10 | 10 | 11 | 11 | 11 | 10 | 10 | 10 | 12 | 11 | 10 | 10 | 10 | 9 | 9 | 10 | 10 | 10 | 11 | 10 | 10 | 13 | 10 | 10 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 8 | 8 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 7 |
| Series | Quarterly | Quarterly | Quarterly | Quarterly | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Annual 2011 to 2014; quarterly Q1 2010 to Q4 2010; monthly Jan 2015 to Aug 2026.
CVR changed its monthly method in Oct 2019, so a step at that month need not be real.
Latest Aug 2026, published 21 Oct 2026. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Not reported | 240,941 | 178,192 | 120,054 | 76,504 |
| Gross profit | 18,854 | Not reported | Not reported | Not reported | Not reported |
| Operating profit | +7,288 | +11,228 | +9,412 | +7,540 | +3,699 |
| Result for the year | +5,273 | +8,499 | +8,088 | +7,712 | +4,668 |
| Equity | 37,587 | 46,084 | 54,168 | 61,880 | 24,026 |
| Total assets | 83,464 | 79,742 | 84,442 | 83,281 | 45,475 |
| Employees (average) | 11 | 10 | 10 | 9 | 9 |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | Not reported | 19.6% | -26% | -32.6% | -36.3% |
| EBIT margin (overskudsgrad) | Not reported | 4.7% | 5.3% | 6.3% | 4.8% |
| EBITDA | 12,516 | 16,475 | 11,450 | 7,956 | 3,767 |
| EBITDA margin (EBITDA-margin) | Not reported | 6.8% | 6.4% | 6.6% | 4.9% |
| Employee growth (vækst i antal ansatte) | 0% | -9.1% | 0% | -10% | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 234note 1 | 226note 1 | Not reportednote 2 | 0note 3 | Not reportednote 2 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions.
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 30 Jun 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 9 Jul 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 28 Jun 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 12 Jul 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 28 Jun 2022
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For Caldic Denmark A/S, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
From CVR, read 13 Nov 2026. Text such as the signing rule and purpose is shown as registered.
From CVR, read 13 Nov 2026. A change is counted each time the registry records a new value, so a corrected address or an audit firm under a new entity counts too.
24 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Bestyrelse:
Fratrådte:
Lars Gustav Larsson, den 11.09.2026.
Tiltrådte:
Peter Kristian Faaborg-Andersen, den 11.09.2026.
Direktion:
Fratrådte:
Lars Gustav Larsson, (adm. dir), den 11.09.2026.
Tiltrådte:
Peter Kristian Faaborg-Andersen, (adm. dir), den 11.09.2026.
Bestyrelse:
Fratrådte:
Hans Robin Daniel Malmros, den 09.07.2025.
Tiltrådte:
Torsten Walz, (formand), den 09.07.2025.
Bestyrelse:
Fratrådte:
Laurent Pasqualini, den 17.01.2025.
Bestyrelse:
Fratrådte:
Niklas Hugo Georg Ekman, den 16.09.2024.
Tiltrådte:
Lars Gustav Larsson, den 16.09.2024.
Direktion:
Fratrådte:
Niklas Hugo Georg Ekman, (adm. dir), den 16.09.2024.
Tiltrådte:
Lars Gustav Larsson, (adm. dir), den 16.09.2024.
Bestyrelse:
Fratrådte:
Johan Sundell, den 06.09.2023.
Bestyrelse:
Fratrådte:
Alexander Wessels, (formand), den 04.11.2021, Bernardus Witte, den 04.11.2021.
Tiltrådte:
Johan Sundell, den 04.11.2021, Laurent Pasqualini, den 04.11.2021, Martin Zemp, den 04.11.2021.
Revision:
Fratrådte:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 19.10.2020.
Tiltrådte:
CVR-NR. 30700228 EY Godkendt Revisionspartnerselskab, Lysholt Allé 10, 7100 Vejle, den 19.10.2020.
Bestyrelse:
Fratrådte:
Olav Caspar van Caldenborgh, (formand), den 19.10.2020.
Tiltrådte:
Alexander Wessels, (formand), den 20.10.2020.
Ny adresse: Mimersvej 1, 8722 Hedensted
Vedtægter ændret: 20.12.2018
Kapitalforhøjelsen er besluttet den 20.12.2018.
kr. 1.000,00, indbetalt ved konvertering af gæld, kurs 1.650.000,00.
Kapitalen udgør herefter kr. 501.000,00.
Bestyrelse:
Fratrådte:
Torben Møller Madsen, den 15.09.2018.
Tiltrådte:
Niklas Hugo Georg Ekman, den 15.09.2018.
Direktion:
Fratrådte:
Torben Møller Madsen (adm. dir), den 15.09.2018.
Tiltrådte:
Niklas Hugo Georg Ekman (adm. dir), den 15.09.2018.
Bestyrelse:
Fratrådte:
Thomas Lind Nielsen, den 27.03.2018, Bernardus Witte (formand), den 27.03.2018, Olav Caspar van Caldenborgh, den 27.03.2018.
Tiltrådte:
Torben Møller Madsen, den 27.03.2018, Bernardus Witte, den 27.03.2018, Olav Caspar van Caldenborgh (formand), den 27.03.2018.
Direktion:
Fratrådte:
Thomas Lind Nielsen (adm. dir), den 27.03.2018.
Tiltrådte:
Torben Møller Madsen (adm. dir), den 27.03.2018.
Revision:
Fratrådte:
MARTINSEN STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 12.08.2016.
Tiltrådte:
CVR-NR. 33771231 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Jens Chr.Skous Vej 1, 8000 Aarhus C, den 12.08.2016.
Vedtægter ændret: 28.04.2016
Nyt navn: Caldic Denmark A/S
Nyt binavn: R2 Group Pharmaceuticals A/S
Bestyrelse:
Fratrådte:
Paul Sebastiaan Veth, den 28.04.2016.
Tiltrådte:
Thomas Lind Nielsen, den 28.04.2016.
Direktion:
Fratrådte:
Olav Caspar van Caldenborgh (adm. dir), den 28.04.2016.
Tiltrådte:
Thomas Lind Nielsen (adm. dir), den 28.04.2016.
Bestyrelse:
Fratrådte:
Peter Skou, den 12.02.2016, Bernardus Witte, den 12.02.2016, Olav Caspar van Caldenborgh (formand), den 12.02.2016.
Tiltrådte:
Bernardus Witte (formand), den 12.02.2016, Olav Caspar van Caldenborgh, den 12.02.2016, Paul Sebastiaan Veth, den 12.02.2016.
Direktion:
Fratrådte:
Peter Skou, den 12.02.2016.
Tiltrådte:
Olav Caspar van Caldenborgh (adm. dir), den 12.02.2016.
Vedtægter ændret: 23.09.2015
Bestyrelse:
Fratrådte:
Thomas Lind Nielsen, den 23.09.2015, Lars Skou (formand), den 23.09.2015.
Tiltrådte:
Bernardus Witte, den 23.09.2015, Olav Caspar van Caldenborgh (formand), den 23.09.2015.
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse..
Vedtægter ændret:
14.01.2013.
Nyt navn:
R2 GROUP PHARMACEUTICALS A/S.
Binavn:
R2 MEDITALIA A/S.
Nyt binavn: R2 PHARMACTIVE A/S.
Ny adresse:
Odinsvej 23, 8722 Hedensted.
Vedtægter ændret:
08.06.2011.
Vedtægter ændret:
26.05.2011.
Revision:
Udtrådt af revisionen:
H. MARTINSEN, STATSAUTORISERET REVISIONSAKTIESELSKAB, den 01.12.2009.
Indtrådt i revisionen:
MARTINSEN STATSAUTORISERET REVISIONSPARTNERSELSKAB, Jupitervej 4, 6000 Kolding, den 01.12.2009.
Binavn:
R2 MEDITALIA A/S (R2 PHARMACTIVE A/S).
Stiftelsesdato:
08.10.2009.
Seneste vedtægtsdato:
08.10.2009.
Kapital:
kr. 500.000,00.
Indbetalingsmåde:
kontant kr. 500.000,00 til kurs 100,00.
Stifter:
CVR-NR. 16545996 RODE & RODE A/S, Odinsvej 25, 8722 Hedensted, den 08.10.2009.
Bestyrelse:
Direktør Lars Skou (formand), den 08.10.2009, Thomas Lind Nielsen, den 08.10.2009, Peter Skou, den 08.10.2009.
Direktion:
Peter Skou, den 08.10.2009.
Selskabet tegnes af direktøren eller 3 bestyrelsesmedlemmer i forening.
Revision:
H. MARTINSEN, STATSAUTORISERET REVISIONSAKTIESELSKAB, Jupitervej 4, 6000 Kolding, den 08.10.2009.
Første regnskabsår:
08.10.2009 - 31.12.2010.
Regnskabsår:
01.01 - 31.12.
1 registered in CVR.
P-number 1015587861Mimersvej 1, 8722 Hedensted